Genocea Biosciences To Host Second Quarter 2015 Financial Results Conference Call & Webcast On August 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will host a conference call and live audio webcast on Thursday, August 6, 2015 at 9:00 a.m. ET to discuss financial results for the second quarter of 2015. The presentation, hosted by Genocea’s President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the Company’s recent progress and upcoming milestones.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 87463451. To join the live webcast please visit the investor relations section of the Genoceea website at http://ir.genocea.com.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 30 days.

About Genocea
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.